SCHEMBL4393318

SCHEMBL4393318

CC(NC(C)(C)CO)C(=O)c1ccc(Br)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.58
SLC6A3 Q01959 6/20 0.48
SLC6A2 P23975 6/20 0.48
CHRNA1 P02708 4/20 0.48
CHRNG P07510 4/20 0.48
CHRNB1 P11230 4/20 0.48
CHRNB2 P17787 4/20 0.48
CHRNB4 P30926 4/20 0.48
CHRNA3 P32297 4/20 0.48
CHRNA4 P43681 4/20 0.48
CHRND Q07001 4/20 0.48
SLC6A4 P31645 4/20 0.48
OGG1 O15527 1/20 0.40
ITGA5 P08648 1/20 0.39
CYP2C19 P33261 1/20 0.39
HRH1 P35367 1/20 0.39
CHRNA7 P36544 1/20 0.39
OPRK1 P41145 1/20 0.39
KCNH2 Q12809 1/20 0.39
LMNA P02545 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770168 0.83 SLC6A3 (0.65) CYP2B6SLC6A3SLC6A2CHRNA1CHRNG
SCHEMBL16992600 0.74 HTR1B (0.49) SLC6A3SLC6A2CHRNA1CHRNGCHRNB1
SCHEMBL20481912 0.74 HTR1B (0.49) SLC6A3SLC6A2CHRNA1CHRNGCHRNB1
SCHEMBL4399949 0.74 CYP2B6 (0.57) CYP2B6SLC6A3SLC6A2CHRNA1CHRNG
SCHEMBL2955630 0.74 CYP2B6 (1.00) CYP2B6SLC6A3SLC6A2CHRNA1CHRNG
SCHEMBL29486913 0.74 CYP2B6 (1.00) CYP2B6SLC6A3SLC6A2CHRNA1CHRNG
SCHEMBL2955633 0.74 CYP2B6 (1.00) CYP2B6SLC6A3SLC6A2CHRNA1CHRNG
SCHEMBL1226857 0.74 CYP2B6 (1.00) CYP2B6SLC6A3SLC6A2CHRNA1CHRNG
SCHEMBL4240834 0.73 OGG1 (0.53) OGG1ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL10656522 0.72 CYP2B6 (0.51) CYP2B6SLC6A3SLC6A2CHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188150-B2 Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain BIOCOPEA LIMITED (GB) 2012-05-29 US disclosed
US-20090306216-A1 Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain BIOCOPEA LIMITED (GB) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306216-A1 Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain OPRL1, HRH3, NR1H2 CYP2B6 1336/4885SLC6A3 2825/4885SLC6A2 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.